Stock Analysis
Johnson & JohnsonJNJ
P/E 29.28×· 5Y range 9.12–35.16×· top 18% of history
Sector: Healthcare · Industry: Drug Manufacturers - General
AnalystsStrong Buy31 analystsP/E 29.3× sits at the 82nd percentile of its 5.086926762491444-year history.
Cash covers 42% of debt · FY 2025.
PMP Verdict
High quality, but expensive
Strengths
- Profitability95
- Financial Health74
Risks
- Valuation36
Excellent business. Weak entry price.
Bull Case
- ✓Altman Z 5.3 — safe-zone balance sheet
- ✓ROE 25.8% — efficient capital deployment
- ✓Interest coverage 24.0× — debt well covered
What's happening with JNJ
Profile
Strong profitability and moat; valuation lags behind.
How is each axis scored?
- Valuation36/100 · Weak
- P/E vs own history (82th pct)0/25
- FCF yield (3.6%)12/25
- P/S (6.3x)12/25
- EV/EBIT (19.3x)12/25
- Growth55/100 · Moderate
- Revenue CAGR (0.1%)6/25
- Net income CAGR (6.4%)12/25
- EPS CAGR 5Y (9.0%)12/25
- Fwd implied growth (32.9%)25/25
- Profitability95/100 · Strong
- ROIC (24.1%)20/25
- ROE (25.8%)25/25
- Net margin (21.5%)25/25
- Operating margin (34.1%)25/25
- Financial Health74/100 · Moderate
- Altman Z (5.35)25/25
- Current ratio (1.03)12/25
- Interest coverage (24.0x)25/25
- Net cash / debt (D/A 14%)12/25
- Quality72/100 · Moderate
- Piotroski F (5/9)15/25
- Beneish M (-2.40)20/25
- FCF conversion (106%)25/25
- Margin stability (σ 9.9%)12/25
- Moat87/100 · Strong
- ROIC >12% years (10/10 yrs)25/25
- Median gross margin (67.6%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 1.7%)12/25
Risk Flags
- ⚠P/E 29.3× at top 18% of 5-year history
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. Show more
It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Headquarters: NEW BRUNSWICK, NJ · Employees: 140,800 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
36DP/E (TTM)29.2xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 9.1x–35.2x · 82nd pct
P/FCF28.1xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield3.6%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 2.9%–6.0% · 18th pct
P/S (TTM)6.28xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 3.9x–6.8x · 93rd pct
EV/EBIT19.3xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 12.0x–31.8x · 33rd pct
EV/Sales6.8xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E22.0xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio7.54xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio3.44D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield2.02%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio60.0%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
95A+ROIC24.1%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE25.8%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA10.6%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin21.5%A
Grade A: HighNet Income / Revenue
Operating Margin34.1%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin67.9%A
Grade A: PremiumGross Profit / Revenue
FCF Margin22.7%A
Grade A: HighFCF / Revenue
True FCF Margin21.3%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
55CRevenue CAGR0.1%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR6.4%C
Grade C: OkCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)9.0%C
Grade C: OkCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth32.9%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-9.9%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income6.7%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.4%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
74B+Altman Z-Score5.35A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.03xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.73xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage24.0xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment1.3yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT0.8xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.59xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.42xC
Grade C: PartialCash covers how much of total debt. >1 = could repay all debt from cash
Quality
72B+Piotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.40A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion105.7%A
Grade A: StrongFCF / Net Income
Margin Stability9.9%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue5.5%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.49xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Woods Eugene A. Filed | Woods Eugene A. | Grant / award | +136 | |
Pinto Daniel E Filed | Pinto Daniel E | Grant / award | +113 | |
HEWSON MARILLYN A Filed | HEWSON MARILLYN A | Grant / award | +181 | |
Schmid Timothy Filed | Schmid Timothy | Option exercise | -22527 | |
Schmid Timothy Filed | Schmid Timothy | Option exercise | -11070 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Schmid Timothy Filed | Schmid Timothy | SellOpen market sale | -22527 | |
Schmid Timothy Filed | Schmid Timothy | Option exercise | +22.5K | |
Schmid Timothy Filed | Schmid Timothy | SellOpen market sale | -11070 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
87AROIC >12% Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)67.6%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor1.7%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$8.73
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$8.62
Cash & short-term investments per share (Finnhub)
Book Value / Share$35.28
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$47.93B
Total debt obligations (short + long term)
Cash & Equiv.$20.10B
Cash and short-term investments
Net Debt$27.83B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$81.54B
Shareholders' equity (book value)
Asset / Liability1.69xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$614.52B
Current Market Capitalization
Beta0.20B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: Johnson & Johnson (JNJ)
JNJ is up 0.90% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Johnson & Johnson. Altman Z-Score of 5.35 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.40 suggests a low likelihood of earnings manipulation.
- Johnson & Johnson converts about 23% of revenue into free cash flow — strong cash generation.
- Takes ~1.3 years to repay net debt from free cash flow.
- Return on equity of 25.8% is well above the market average.
- The stock currently yields 2.0% in dividends.
See how JNJ ranks on the Capex Tracker — top 50 capital spenders compared.
Earnings
View earnings calendar →Recent Earnings Results
| Date | Time | EPS Est. | EPS Actual | Surprise | Rev Est. | Rev Actual |
|---|---|---|---|---|---|---|
| Oct 13, 2026 | After-Hrs | $2.56 | $2.59 | +1.0% | $25.5B | $25.4B |
Recent Market Moves
See all JNJ moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 13 | Regular | 248.99 | -5.59% | -5.44 |
| Oct 13 | After-hours | 249.22 | -5.50% | -5.35 |
| Oct 9 | Regular | 260.80 | +1.68% | 2.02 |
| Oct 9 | After-hours | 261.79 | +2.07% | 2.43 |
| Oct 7 | Regular | 258.71 | +1.54% | 2.15 |
Frequently Asked Questions about JNJ
What is the current Johnson & Johnson (JNJ) stock price?
JNJ is trading at $255.56 at the last market close, up 0.90% on the session. PreMarketPrice tracks JNJ pre-market, intraday and after-hours prices.
Is JNJ stock a buy right now?
PreMarketPrice's quantitative model rates Johnson & Johnson's financial health at 74/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is JNJ stock overvalued?
Johnson & Johnson trades at a trailing P/E of 29.2 and our valuation score rates it 36/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Johnson & Johnson report earnings?
No confirmed earnings date is currently scheduled for JNJ. The Earnings section lists recent reports and updates as dates are announced.
What sector does Johnson & Johnson operate in?
Johnson & Johnson operates in the Healthcare sector, within the Drug Manufacturers - General industry. The Related Stocks section lists sector peers for comparison.
What does Johnson & Johnson do?
Johnson & Johnson is the world's largest and most diverse healthcare firm.
About Johnson & Johnson (JNJ) Stock
Johnson & Johnson (JNJ) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry. As of the latest update, Johnson & Johnson is trading at $255.56, up 0.90% on the day with a market capitalization of $614.5 billion. The financial health score for JNJ is 74/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for JNJ stock.
JNJ Stock Analysis & Key Metrics
On PreMarketPrice, you can track Johnson & Johnson (JNJ) across multiple dimensions:
- Pre-market price & movement: Real-time JNJ stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Earnings calendar: Upcoming and past earnings reports for JNJ, including EPS estimates, actual results, and surprise percentages.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for JNJ with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Johnson & Johnson across multiple reporting periods.
- Financial health score: A composite score of 74/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for JNJ.
- Sector peers: Compare JNJ against 6 other healthcare stocks on key financial metrics.
Is JNJ a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Johnson & Johnson (JNJ) as an investment. The financial health score of 74/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average. Earnings data reveals whether the company is meeting or beating analyst expectations.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Johnson & Johnson (JNJ) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.